76 results about "Kidney Toxicity" patented technology

Kidney toxicity which is induced by cisplatin and other therapeutic and diagnostic agents, limits the effectiveness of the therapy or diagnosis. Modulation or depletion of T cells ameliorates the toxicity, permitting the use of cisplatin at levels and for durations which treat cancers more effectively. Modulation and depletion can be accomplished using antibodies for T cell surface antigens as well as using other molecules which effectively antagonize or down-regulate the cytokines and / or chemokines which T cells elaborate.

The invention relates to the technical field of traditional Chinese medicines, and provides application of quercetin in preparing a medicine for treating polycystic ovarian syndrome. A test is performed on a rat model with polycystic ovarian syndrome by adopting quercetin, and discovers that the quercetin has a remarkable treatment effect and can remarkably reverse insulin resistance. Quercetin does not have liver or kidney toxicity, is small in side effect, has a good clinical application prospect, does not have drug resistance, can avoid operative wounds, and obtains an excellent clinical effect in PCOS (polycystic ovary syndrome) treatment.

The invention relates to a method for evaluating kidney toxicity of compounds through detecting the contents of creatinine in zebra fish tissues. The method is applied to kidney toxicity researches. In the researches that utilize a zebra fish embryo model to study the toxic effect of compounds on the kidney, the creatinine component in embryo tissues is extracted, then the creatinine content is measured through a LC-MS (liquid chromatography-mass spectrum) method, the creatinine content can be taken as a detection index for evaluating the embryo kidney functions, and thus a rapid and precise compound kidney toxicity evaluation system with strong specificity is built.

The invention belongs to the field of pharmacotherapeutics, and particularly relates to application of 18 beta-glycyrrhetinic acid (or salt) for serving as an auxiliary treating drug capable of easing acute kidney injury caused by a chemotherapeutic drug, namely cis-platinum, wherein the 18 beta-glycyrrhetinic acid (or salt) is one of the main components of liquorice. The cis-platinum serves as a commonly-used chemotherapy drug, and clinical application thereof is restricted by kidney toxicity thereof. The levels of creatinine and urea nitrogen in the acute kidney injury induced by the cis-platinum can be inhibited by the18 beta-glycyrrhetinic acid, expression of KIM-1 injured protein is lowered, and apoptosis of renal tubular epithelial cells caused by the cis-platinum is inhibited. According to the application of the 18 beta-glycyrrhetinic acid (or salt) for serving as the auxiliary treating drug capable of easing the acute kidney injury caused by the chemotherapeutic drug, namely the cis-platinum, the effect that the 18 beta-glycyrrhetinic acid has a protecting effect on the acute kidney injury caused by the cis-platinum is discovered for the first time, a mechanism of the 18 beta-glycyrrhetinic acid is related to inhibiting of apoptosis of the renal tubular epithelial cells, and a novel potential drug is provided for Chinese medicine anti-cancer adjuvant therapy.

Liuwei Dihuang Pill is a Chinese medicinal preparation based on ancient prescription, but alisol, one of its ingredients has the side effect of causing nausea, emesis, dizziness, abdominalgia, myasthenia of limbs and other diseases. By substituting alisol with bark of boxthron-root, the invention provides another Liuwei Dihuang preparation for sustaining the action of body fluid reinforcing and kidney tonifying, and preventing adverse effects of alisol.

The invention discloses an allogeneic bone cement for bone defect repair, which is composed of a component A and a component B, wherein the component A is prepared by mixing allogeneic muscle tendon collagen fibers and allogeneic bone particles according to a ratio of 1:(2-8); the component B is a colorless, transparent and viscous sodium hyaluronate solution of which the pH value is 6-7 and the concentration is 5-20mg / ml; and the component A and the component B are mixed according to a ratio of 1g:(1.5-3.5)ml. The allogeneic bone cement has good biological activity and biodegradability, has no kidney toxicity, has fine osteoinduction and osteophony effects, and is convenient to use, thereby being widely used in the field of bone defect repair.

The invention relates to an ibuprofen nanoparticle with low renal toxicity and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The nanoparticle is prepared by placing ibuprofen, a plant-derived functional natural product auxiliary material, a flow aid and ball-milling beads in a ball-milling tank and carrying out a co-grinding reaction at a certain rotating speed, and the ibuprofen is uniformly entrapped in a carrier under the action of mechanical force, so that an ibuprofen nanoparticle product with low renal toxicity is obtained. According to the ibuprofen nanoparticle and the method, the nanoparticle is prepared through a limited preparation method, the operation is simple, the use of an organic solvent is avoided, the problems about raw material loss, thermal decomposition and the like caused by solvent residues and a solvent thermal removal process are prevented, and the advantages of high preparation efficiency, safe and reliable production, low production cost, less pollution and the like are achieved; and meanwhile, a plant-derived macromolecule is adopted as the carrier, so that the renal toxicity of the ibuprofen is reduced while solubilization and synergism are achieved, and the macromolecule is of great importance to safe medication of a non-steroidal anti-inflammatory drug.

The invention relates to the use of schisandra fruit in preparing medicament for prevention and abatement of toxic and side effects of antineoplastic drugs including cardiovascular toxicity, liver toxicity, kidney toxicity, or bone marrow depression, or immunological suppression or trichomadesis.

The present invention provides a conjugate of tenofovir, addy adefovir and intelligent polymers, a method for preparing the same, and an usage. The invention relates to the technical field that antiviral medicinal molecular tenofovir and addy adefovir are chemical modified, namely, phosphate group of tenofovir or addy adefovir is linked with X group, then X group is linked with intelligent polymers R, or phosphate group of tenofovir or addy adefovir is linked with intelligent polymers R with X function group, and a conjugate of tenofovir, addy adefovir and intelligent polymers with A-X-R-Y formula is formed. The modified tenofovir and addy adefovir forms efficient screen for raw medicine, and improves obviously medicine absorption of intestinal and absorption of cell, improves bioavailability of medicine, at the same time, reduces the kidney cleaning of medicine, and reduces the toxic for kidney, improves security.

The invention discloses a honeybee pupae extract and application in protecting against cisplatin induced kidney injury, and relates to the technical field of honeybee pupae and application. Accordingto the invention, the honeybee pupae extract is firstly prepared and then a product of the honeybee pupae extract is applied to treat the cisplatin induced kidney injury, and has the effects of treating the cisplatin induced kidney injury. An experiment finds that the honeybee pupae extract has extremely-high free radical scavenging activity and can improve the activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in an organism. By inhibiting a molecular mechanism of inducing by cisplatin to form superoxide free radicals, the effect of reducing renal toxicity is achieved; meanwhile, the honeybee pupae extract has extremely-high nutritional value, so that animal physique can be improved and the immunity is enhanced; in addition, because the honeybee pupae extract isderived from active ingredients in the organism, the honeybee pupae extract has medicine and food dual-purpose function, and no toxic or side effects, can be obtained through ingestion and is expectedto be further developed as a safe and reliable treatment drug.

The invention discloses an extract enriched in benzopyran lactone as well as a preparation method and medical application of the extract. The extract provided by the invention is enriched in gastrodinA, gastrodin B and gastrodin C, wherein the sum of contents of the three is not lower than 90%; or the extract is enriched in gastrodin A, gastrodin B, gastrodin C and gastrodin D, and the sum of contents of the four is not lower than 85%. The extract is clear in monomer composition, high in content and capable of easily controlling the quality, the renal toxicity of aristolochic acid can be reduced, and the extract can be used for preparing a single Chinese herb containing aristolochic acid or a traditional Chinese medicine tract or an attenuated drug of a traditional Chinese medicine compound preparation. According to the preparation method of the extract, disclosed by the invention, separation methods that are difficult to operate on a large scale in a factory, such as column chromatography on silica gel, do not need to be repeatedly used, the extract with the total content 85% or higher of effective monomer composition can be prepared by only passing through a primary macroporousresin and combining with pH regulation and control, and the preparation method is capable of easily realizing industrialization, simple in operation and low in cost.

The invention discloses a preparing method of biphenyl cyclo-octadiene lignans and application in the tumour prevention drug, which is characterized by the following: reducing cardiovascular toxicant or liver toxicant or kidney toxicant or marrow inhibition or immune inhibition or alopecia, adopting schizandrin to lessen side-effect of tumour prevention drug effectively.

The invention discloses a pharmaceutical composition for relieving malaise after chemoradiotherapy and a preparation method thereof. The traditional Chinese medicine composition comprises the following medicinal materials: codonopsis pilosula, astragalus membranaceus, Chinese yam, liquorice, Chinese-dates, acanthopanax, sea-buckthorn, human placenta, thellung pimpinella herb, arillus longan, lily, radix ophiopogonis, mulberry, light wheat, schisandra chinensis, lotus seed, poria with hostood, valerian, vine of multiflower knotweed, gynostemma pentaphylla, lucid ganoderma, vicia sativa and cortex albiziae. The pharmaceutical composition disclosed by the invention has the beneficial effects that the pharmaceutical composition is used for benefiting vital energy and nourishing the heart as primary functions, and tonifying the stomach and spleen and sterilizing and detoxifying as auxiliary functions by using the theory of the traditional Chinese medicine in China, the immune system of the organism can be improved, the myocardial function is protected, the gastrointestinal reaction is reduced, the renal toxicity is reduced, the liver is protected, the pathogenic factor resisting abilities, of disinfecting, sterilizing and the like, of the body are improved, and the pharmaceutical composition has the effects of being good in effect, quick to take effect, high in safety and free of toxic and side effects in the aspect of relieving malaise after chemoradiotherapy.

The invention provides application of a traditional Chinese medicine composition in preparation of a medicament for treating renal toxicity after chemoradiotherapy and cardiovascular and cerebrovascular diseases. The traditional Chinese medicine composition comprises the components, namely rheum officinale, astragalus membranaceus and root of red-rooted salvia. An experiment proves that the traditional Chinese medicine composition effectively treats and relieves renal toxicity caused by tumor radiation and chemotherapy, and simultaneously has an obvious treatment effect on ischemic cardiovascular and cerebrovascular diseases, for example, cerebellar infarction size is reduced, the cerebral ischemic injury is improved, the infarct size of myocardial ischemia reperfusion in rats is reduced, and the content of methylene dioxyamphetamine (MDA) and NOS is reduced.

The invention discloses a drug for treating multiple myeloma and especially relates to a use of itraconazole or its salts in preparation of a drug composition for treating multiple myeloma. It is accidentally discovered that itraconazole has effects of treating multiple myeloma. A treatment principle of itraconazole comprises that itraconazole mainly acts on a cancer cell Hedgehog (Hh) signal path and inhibits accumulation of Smoothened (Smo) protein in the cancer cell Hedgehog (Hh) signal path thereby inhibiting growth of cancer cells. Compared with bortezomib, itraconazole has small liver and kidney toxicity. Accidental death is not produced due to drug toxicity in a mouse test. A result of a clinical experiment shows that itraconazole has effects of treating various types of multiple myeloma and especially has good treatment effects after bone marrow transplantation. Results of treatment on 30 clinical tested patients show that a total effective rate is 95.9%. In addition, through combination with bortezomib, itraconazole has better effects.

The invention discloses a low-renal-toxicity protein-ferric oxide composite nano magnetic resonance contrast agent as well as a preparation method and application thereof, and belongs to the technical field of medical materials. The preparation method of the magnetic resonance contrast agent comprises the following steps: mixing functional protein with a ferric salt solution formed by mixing Fe < 2 + > and Fe < 3 + >, and adding a NaOH solution into the mixed solution or sequentially adding the NaOH solution and an excessive hydrogen peroxide solution, so that the protein-ferric oxide composite nano magnetic resonance contrast agent can be prepared by a one-pot in-situ method. The contrast agent takes ferric oxide as a core, and the functionalized protein is wrapped on the core, so that the contrast agent has high uniformity, hydrophilicity and monodispersity, low renal toxicity and good biocompatibility, and can be used as a safe magnetic resonance contrast agent.

The invention discloses an argatroban liposome injection which is mainly prepared from the following components in parts by weight: 1 part of argatroban, 0.1-0.3 part of sodium hydroxide, 10-25 parts of phospholipid, 5-8 parts of phosphatidyl glycerol, 5-10 parts of cholesterol and 5-10 parts of Tween 80, wherein the phospholipid is one of soybean lecithin, phosphatidylethanolamine, dicetyl phospholipid and soybean phosphatidylserine, the solubility of argatroban in a solution is remarkably enhanced, and meanwhile, the use of an organic solution is reduced by virtue of the use of specific lipidosome, so that the toxicity of the injection is improved, and the problem of renal toxicity of the traditional argatroban injection is solved.

The invention belongs to the technical field of drug concentration monitoring, and relates to a method for simultaneously determining concentrations of vancomycin and a crystalline degradation productCDP-1 in human serum by LC-MS / MS. According to the method, norvancomycin is used as an internal standard, formic acid is used for acidifying serum, quantitative acetonitrile precipitated protein is added, acetonitrile and formic acid water are used as mobile phases, and the concentrations of human serum vancomycin and CDP-1 are determined through an LC-MS / MS method. According to the method, the sampling amount is small, and pretreatment is simple and rapid. The method can be used for determining the concentrations of vancomycin and degradation products CDP-1 in serum samples of conventional clinical patients. Particularly, different degrees of CDP-1 generated after hemodialysis of patients with renal insufficiency can be quantified, so that the concentration of the antibacterial active ingredient vancomycin is reduced, an individualized vancomycin dosing scheme can be made and adjusted clinically, the clinical curative effect and the bacterial clearance rate can be improved, the generation of bacterial drug resistance is reduced, and toxic and side effects such as renal toxicity and the like are reduced.

The invention relates to a glomerulus system based on a micro-fluidic chip and applications of the glomerulus system. The micro-fluidic chip is composed of a left main channel, a right main channel, acollagen channel, a collagen channel inlet, a left main channel inlet and a right main channel inlet, wherein the left main channel is connected to the left side of the collagen channel, and the right main channel is connected to the right side of the collagen channel; the left main channel is inoculated with a glomerulus micro-tissue, the right main channel is used as a collecting area, the filtering effect of the glomeruli can be observed, and the influences of the renal toxicity caused by the chemical ingredients on the filtering function of the glomeruli also can be observed. According tothe technical scheme, the construction of a glomerulus chip with the filtering function outside the body is realized, and the application in the kidney toxicity evaluation of the medicines is also realized.

The invention provides an application of tetrahydropalmatine in preparation of medicine for resisting cisplatin toxicity. The toxicity comprises kidney toxicity, ototoxicity and neurotoxicity. The research shows that tetrahydropalmatine has inhibition effect for OCT2 and MATE1, can antagonize the cytotoxicity caused by cisplatin, and obtains good verification for primary culture of a renal tubular epithelial cell model. By taking (-)-THP as a representative, the research finds that tetrahydropalmatine has good protection effect for mice kidney damage caused by cisplatin, so that tetrahydropalmatine and cisplatin are combined, accumulation of cisplatin at kidney, cochlear cells and dorsal root ganglion is reduced, so that the expection result for preventing or reducing cisplatin toxicity can be achieved. The application develops the novel purpose of the tetrahydropalmatine, because that OCT2 is highly expressed by kidney, cochlear cells and dorsal root ganglion, expression of OCT2 is lacked on tumor cells, cisplatin has certain passive permeability, so that tetrahydropalmatine and cisplatin are combined, toxicity due to cisplatin is decreased, and cisplatin antineoplastic effect is not reduced.

Six-ingredient rehmannia pill is a famous ancient medicine which is applied for almost a thousand years, and is also a popular drug which is often taken by people for a long term in pursuit of health care and body building, however, alisma in the raw material medicine can cause gastroenteritis, nausea, vomiting, dizziness, eye faint, abdominal pain, diarrhea, limb weakness, loss of appetite, itching, angioedema, allergic skin rashes or even respiratory paralysis and other poisoning symptoms. The ancient and modern medical literature points out that the alisma can not be taken for a long term or with a large amount at early time, or else, the long-term taking of the alisma can also cause sever side effects such as kidney toxicity and thus resulting in acute tubular necrosis and the like. The traditional Chinese medicine phellodendron has the function of reducing renal fire of the alisma in the six-ingredient rehmannia pill. The six-ingredient rehmannia pill is used to replace the alisma, is improved into a new six-ingredient rehmannia pill, not only can maintain the functions of nourishing yin and tonifying the kidney of the ancient six-ingredient rehmannia pill, but also can avoid adverse reactions caused by the use of the alisma, thereby being conducive to improving the safety of the medicine and being capable of obtaining a considerable amount of market share in the competition with the original six-ingredient rehmannia pill.

The invention relates to a pH-responsive amphotericin B derivative as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical chemistry preparation. According to the derivative of the invention, the amphotericin B derivative with a novel structure is obtained by modifying amino on trehalosamine in an amphotericin B molecule, and compared with non-modified amphotericin B, the amphotericin B derivative has the characteristics of low renal toxicity, small hemolysis and high safety. In addition, the invention further provides a preparation method of the derivative, the yield is high as well, and the prepared derivative has a good antifungal effect and has a wide market prospect in the aspect of treating systemic deep fungal infection.

The invention discloses a pharmaceutical composition for treating acute kidney failure, which comprises (by weight ratio) 10.0-25.0 of Xiangdan injection, 1.0-5.0 of glycine, and 70.0-88.0 of physiological saline solution. The composition can be prepared into various dosage forms including injection, powder preparation, tablet, and capsule.

The invention relates to a novel CT contrast medium and a preparation method and application thereof. The CT contrast medium is phospholipids PEG-modified BaHoF5 particles. The CT contrast medium disclosed by the invention contains elements Ba and Ho, and the advantages of the two elements are combined. Compared with the existing iodine-based contrast medium, the novel CT contrast medium has the advantages of excellent contrast effect, small use amount and low kidney toxicity; furthermore, by use of the hydrophilic modification of phospholipids PEG for the BaHoF5 particles, the biocompatibility of the contrast medium is improved, the toxic and side effect is reduced, and the blood circulating performance is promoted.

The invention provides applications of Shenkang injection in preparation of medicaments used for prevention or treatment of kidney toxicity caused by radiotherapy or chemotherapy. The injection comprises, by weight, the following drug ingredients: 7 to 15 portions of rheum officinale, 6 to 15 portions of red sage root, 8 to 15 portions of safflower and 15 to 45 portions of radix astragali. An experiment confirms that the Shenkang injection of the invention mayhelp to decrease serum creatinine and urea nitrogen content of animals after radiotherapy or chemotherapy, and decrease urine protein content of rats after chemotherapy. Clinical experiments confirm that the Shenkang injection has substantial effects in treatment of patients with renal toxicty caused by radiotherapy or chemotherapy.

The invention discloses a preparation method and application of an array sensor for instantaneously recognizing drug-induced HK-2 cell damage, and the preparation method comprises the following steps:adding dopamine hydrochloride and polyethyleneimine into a buffer solution, uniformly mixing and stirring, filtering and dialyzing to obtain a polydopamine-polyethyleneimine copolymer carrier with excellent quenching effect; wherein three kinds of QDs with different emission wavelengths can be adsorbed through electrostatic interaction, fluorescence of the QDs is quenched, and the multi-channel sensor is formed. Different renal toxicity drugs act on cells, substances on the surfaces of cell membranes are changed, the sensor QDs is induced to dissociate, a characteristic fluorescence fingerprint spectrum is formed, and a drug damage mechanism is rapidly identified by means of a multivariate statistical method. Based on the time-effect relationship of drug damage, fluorescence signals at different times are detected, a dynamic fluorescence fingerprint is drawn, and accurate typing of drug-induced renal cell damage is further realized. The sensor provides a new tool and a new method forrapidly exploring a renal toxicity mechanism of a drug.

The invention relates to an application of maggot or extract thereof in preparation of a medicine for reducing renal toxicity. The invention also provides a pharmaceutical composition for reducing renal toxicity. The pharmaceutical composition comprises the maggot or extract thereof and riboflavin.

The invention discloses food suitable for acid-base equilibrium of uric acid, which relates to the technical field of a homologous formula of medicine and food and novel resource food. According to the formula, by considering constitutive characters of a patient with high uric acid, various traditional Chinese medicines of the homology of medicine and food are reasonably combined according to the quintessence theory of the traditional Chinese medicine, by adopting a traditional Chinese medicine extraction and special storage and natural fermentation principle, the food is produced by combining active molecules such as deep sea oligopeptide, spirulina and the like and mixing oil with a healthcare function, various vitamins and minerals, when eating the food, people do not need to avoid certain food, active ingredients can eliminate kidney toxicity in the human body, the taste is good, and the food can be eaten for a long time, meets the requirement of modern life, not only can be used as a single nutritional source to meet the nutritional need of the patient with high uric acid, but also has functions of inducing diuresis to alleviate edema, clearing away the heat, inducing dieresis, excreting dampness, checking diarrhea, nourishing and activating the blood, invigorating the spleen, reinforcing stomach, dispelling the humidity and improving the immunity. The preparation process is reasonable, simple, environmentally-friendly and easy for realizing the industrialized mass production.

The invention discloses a nanostructure lipid preparation for improving doxorubicin tumor active targeting and kidney protection and a preparation method. The preparation method comprises the steps ofdissolving salvianolic acid A, doxorubicin hydrochloride and a surfactant in deionized water to prepare a water phase; dissolving an emulsifier and distearoyl phosphoethanolamine-polyethylene glycol-E-[c(RGDfK)2] in a first organic solvent to prepare a first solution; dissolving lipid and distearoyl phosphoethanolamine-polyethylene glycol-folic acid in a second organic solvent to prepare a secondsolution, combining the first solution and the second solution, and performing uniform stirring to prepare an oil phase; and dropwise adding the oil phase into the water phase, then performing heating to remove the organic solvent, and performing cooling to obtain the nanostructure lipid preparation. The nanostructure lipid preparation for improving doxorubicin tumor active targeting and kidney protection prepared by the invention has the advantages of relatively small and uniform particle size, strong tumor targeting, enhanced anti-tumor effect and reduced renal toxicity.

The invention discloses a novel nano sustained-release drug-loaded material for inhibiting antibody-mediated rejection reaction in a targeted immune hair growth center, a preparation method and application. The novel nano drug-loaded material has targeting property, can slowly release drugs, can be used for treating inflammatory infiltration of transplanted organs, and is low in toxicity (low in neurotoxicity and renal toxicity) and small in side effect.